ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Coherus Oncology's annualizedNet Income for the quarter that ended in Mar. 2026 was €-132.61 Mil.
Coherus Oncology's average Total Assets over the quarter that ended in Mar. 2026 was €225.37 Mil. Therefore, Coherus Oncology's annualized ROA % for the quarter that ended in Mar. 2026 was -58.84%.
The historical rank and industry rank for Coherus Oncology's ROA % or its related term are showing as below:
FRA:8C5'
s ROA % Range Over the Past 10 Years
Min: -159.75 Med: -40.3 Max: 50.3
Current: 50.3
During the past 13 years, Coherus Oncology's highest ROA % was 50.30%. The lowest was -159.75%. And the median was -40.30%.
FRA:8C5's ROA % is ranked better than 98.66% of 1418
companies
in the Biotechnology industry
Industry Median: -32.87
vs FRA:8C5: 50.30
Coherus Oncology (FRA:8C5) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
Coherus Oncology ROA % Related Terms
Coherus Oncology ROA % Historical Data
* Premium members only.
The historical data trend for Coherus Oncology's ROA % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Coherus Oncology's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Coherus Oncology ROA % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Coherus Oncology's ROA % distribution charts can be found below:
* The bar in red indicates where Coherus Oncology's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
ROA % is displayed in the 30-year financial page.
Coherus Oncology (FRA:8C5) has a ROA % of -58.84% as of Mar. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Coherus Oncology and its competitors. According to the industry distribution chart, Coherus Oncology ranks #19 out of 1418 companies in the Biotechnology industry, placing it in the top 1.3%.
Is Coherus Oncology's ROA % too high?
Coherus Oncology's current ROA % is -58.84%. Based on the distribution chart, Coherus Oncology ranks #19 out of 1418 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Coherus Oncology has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Coherus Oncology's ROA % compare to TARA and KPTI?
According to the Biotechnology industry distribution chart, Coherus Oncology ranks #19 out of 1418 companies for ROA %. This places Coherus Oncology in the top 1% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Biotechnology company?
A good ROA % depends on the Biotechnology industry context. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Coherus Oncology and its competitors. Coherus Oncology's current ROA % is -58.84%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coherus Oncology stock overvalued right now?
Based on GuruFocus' analysis, Coherus Oncology (FRA:8C5) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.69, compared to a current price of €1.26 — trading 82.2% above its estimated fair value. The current ROA % is -58.84%. Coherus Oncology's overall GF Score™ is 45/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Coherus Oncology (FRA:8C5), the current ROA % is -58.84% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Coherus Oncology (FRA:8C5) Overvalued in 2026?
Based on GuruFocus' analysis, Coherus Oncology stock appears to be overvalued.
The current stock price of €1.26 is trading 82.2% above its estimated GF Value™ of €0.69.
GuruFocus considers Coherus Oncology to be Significantly Overvalued.
Key valuation signals for FRA:8C5:
ROA %: -58.84%
GF Value™: €0.69 vs. price of €1.26 (82.2% above fair value)
No single metric tells the full story. See the FRA:8C5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.
45GF Score
Get the complete analysis for FRA:8C5
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:8C5 has been successfully added to your 
